NasdaqGS:VTYXPharmaceuticals
Ventyx Biosciences (VTYX) Is Up 48.2% After Positive Phase 2 Data for Oral Cardiometabolic Therapy – Has The Bull Case Changed?
Ventyx Biosciences recently announced positive topline results from its Phase 2 clinical trial of VTX3232, showing significant reductions in key inflammatory biomarkers such as hsCRP and IL-6 in patients with obesity and cardiovascular risk factors.
An interesting insight from the study is that VTX3232 achieved a robust safety and tolerability profile, both as a standalone therapy and in combination with semaglutide, highlighting its potential as a new oral anti-inflammatory option in...